Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.43 |
| ▸ | KDM5A | P29375 | 4/20 | 0.43 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923425 | 0.89 | PKM (0.46) | KDM5AC3AR1KMT2A | |
| SCHEMBL4922422 | 0.89 | PKM (0.46) | KDM5AC3AR1KMT2A | |
| SCHEMBL8474235 | 0.87 | SCN9A (0.45) | KMT2A | |
| SCHEMBL8493039 | 0.87 | SCN9A (0.45) | KMT2A | |
| SCHEMBL8474193 | 0.85 | DPP4 (0.55) | — | |
| SCHEMBL8474122 | 0.85 | DPP4 (0.55) | — | |
| Trifluoroacetic Acid SCHEMBL4922189 | 0.82 | DPP4 (0.50) | — | |
| Trifluoroacetic Acid SCHEMBL4916271 | 0.82 | DPP4 (0.50) | — | |
| SCHEMBL4919769 | 0.80 | KDM5A (0.42) | KDM5BKDM5AC3AR1EPHX2KMT2A | |
| SCHEMBL4913816 | 0.80 | KDM5A (0.42) | KDM5BKDM5AC3AR1EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275086-A1 | Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-11-06 | — | — | US | disclosed |
| EP-1702916-A1 | DPP-IV inhibitors | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275086-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | KDM5B 716/4885KDM5A 1036/4885C3AR1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.